Internal Medicine, Nephrology · West Hollywood, CA
NPI
1720134695
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
948 N Fairfax Ave, # 201
West Hollywood, CA, 90046
Phone (323) 654-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$912K
28,820 services
Medicare patients, 2024
731
Average age 79
Drug cost, 2024
$14.8M
59,388 prescriptions
Company payments, 2025
$3,601
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Barats was code J1306 (injection, inclisiran, 1 mg), 6,248 times for 11 patients. In total Mark Barats billed 28,820 services in 77 codes, and Medicare paid $912K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-05-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 6,248 | 11 | $9.54 | $60K |
| 81002 Clinical Chemistry | Office | 2,256 | 660 | $3.41 | $7,693 |
| 96366 Intravenous Infusion, Hydration | Office | 2,063 | 297 | $18.05 | $37K |
| 99214 Office E&M - Established | Office | 1,668 | 614 | $107.71 | $180K |
| 36415 Venipuncture Blood Collection | Office | 1,155 | 568 | $8.65 | $9,991 |
| 96365 Intravenous Infusion, Hydration | Office | 1,059 | 304 | $56.76 | $60K |
| 99215 Office E&M - Established | Office | 1,052 | 494 | $151.04 | $159K |
| 99213 Office E&M - Established | Office | 904 | 345 | $77.78 | $70K |
| 96372 Injection Administration | Office | 694 | 290 | $12.37 | $8,587 |
| G0179 Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 411 | 198 | $35.51 | $15K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 409 | 409 | $140.20 | $57K |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 385 | 204 | $1.01 | $389 |
| 99212 Office E&M - Established | Office | 384 | 226 | $48.98 | $19K |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 361 | 356 | $95.26 | $34K |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 298 | 198 | $44.35 | $13K |
By year: 2022 $872K for 22,644 services; 2023 $838K for 23,489 services; 2024 $912K for 28,820 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 2,256 | 660 | $3.41 | $7,693 |
| 36415 Venipuncture Blood Collection | 1,155 | 568 | $8.65 | $9,991 |
| 87502 Infectious Agent Detection by DNA/RNA | 35 | 34 | $93.88 | $3,286 |
| 87635 COVID Specific | 29 | 29 | $50.28 | $1,458 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark Barats prescribed most often to Medicare patients was Diclofenac Sodium, with 1,711 prescriptions and refills. In total Mark Barats wrote 59,388 Medicare prescriptions that cost $14.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diclofenac Sodium Generic | 1,711 | 1,807 | 206 | $1.2M |
| Febuxostat Generic | 1,683 | 1,715 | 201 | $124K |
| Rosuvastatin Calcium Generic | 1,649 | 1,764 | 194 | $5,088 |
| Amlodipine Besylate Generic | 1,156 | 1,249 | 129 | $1,241 |
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | 1,023 | 1,053 | 106 | $990K |
| Repatha Sureclick Evolocumab | 1,003 | 1,041 | 105 | $568K |
| Icosapent Ethyl Generic | 963 | 985 | 108 | $167K |
| Levothyroxine Sodium Generic | 955 | 1,027 | 103 | $3,944 |
| Lidocaine Generic | 882 | 888 | 100 | $123K |
| Dexlansoprazole Dr Dexlansoprazole | 859 | 869 | 101 | $148K |
| Olmesartan Medoxomil Generic | 819 | 863 | 111 | $5,082 |
| Nebivolol Hcl Generic | 767 | 803 | 86 | $31K |
| Gabapentin Generic | 757 | 764 | 92 | $2,586 |
| Indapamide Generic | 738 | 772 | 81 | $3,978 |
| Linzess Linaclotide | 730 | 746 | 81 | $394K |
Brand drugs: 14,454 claims; generic drugs: 44,462 claims; opioid claims: 588.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Barats $3,601 ($3,601 in general payments such as food, travel and fees) from 29 companies. The largest payer was Amgen Inc. with $637.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 47 | $637 |
| Ardelyx, Inc. ARDX | 14 | $417 |
| Abbvie Inc. ABBV | 15 | $333 |
| Lilly USA, LLC LLY | 9 | $249 |
| Eisai Inc. 4523.T | 9 | $237 |
| Lundbeck LLC | 8 | $214 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $175 |
| Sumitomo Pharma America, Inc. 4506.T | 7 | $152 |
| Axsome Therapeutics, Inc. AXSM | 7 | $145 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $129 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.